Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Abcellera Biologics Inc reports results for the quarter ended in June - Earnings Summary

* Abcellera Biologics Inc  ABCL.OQ  reported a quarterly
adjusted
loss of 11 cents​​ per share for the quarter ended in June. The
mean expectation of eight analysts for the quarter was for a
loss of 13 cents per share.
    * Revenue fell 78.1% to $10.06 million from a year ago;
analysts
expected $12.37 million. 
    * Abcellera Biologics Inc's reported EPS for the quarter was
a
loss of 11 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Abcellera Biologics Inc shares had risen by 7.4% this
quarter and lost 31.5% so far this year.
    * The company reported a quarterly loss of $30.53 million.
    * Wall Street's median 12-month price target for Abcellera
Biologics Inc is $27.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 3 at 09:02 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.13          -0.11          Beat
 Mar. 31 2023      -0.14          -0.14          Met
 Dec. 31 2022      -0.01          -0.10          Missed
 Sep. 30 2022      0.05           0.08           Beat

Recent news on AbCellera Biologics

See all news